Passage Bio to Present at 12th Annual Wedbush PacGrow Healthcare Conference
04 août 2021 07h00 HE
|
Passage Bio
PHILADELPHIA, Aug. 04, 2021 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for rare, monogenic...
Passage Bio to Report Second Quarter 2021 Financial Results on August 5, 2021
29 juil. 2021 07h00 HE
|
Passage Bio
PHILADELPHIA, July 29, 2021 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for rare, monogenic...
Passage Bio Announces Inducement Award for Newly Appointed Chief Commercial Officer Under Nasdaq Listing Rule 5635(c)(4)
21 juil. 2021 07h00 HE
|
Passage Bio
PHILADELPHIA, July 21, 2021 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for rare, monogenic...
Passage Bio Announces Key Executive Appointments
19 juil. 2021 07h00 HE
|
Passage Bio
PHILADELPHIA, July 19, 2021 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for rare monogenic central...
Derrell D. Porter, M.D., Elected to Board of Directors of Passage Bio
01 juin 2021 07h00 HE
|
Passage Bio
PHILADELPHIA, June 01, 2021 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for rare, monogenic...
Passage Bio to Participate in Upcoming June Investor Conferences
26 mai 2021 07h00 HE
|
Passage Bio
PHILADELPHIA, May 26, 2021 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for rare, monogenic central...
Passage Bio Announces Pre-Clinical Data Presentation at Annual ASGCT Meeting
11 mai 2021 06h30 HE
|
Passage Bio
Passage Bio collaborator University of Pennsylvania’s Gene Therapy Program to present poster regarding development of a novel mouse model for evaluating efficacy of adeno-associated virus gene therapy...
Passage Bio to Host Virtual R&D Event on May 17
10 mai 2021 07h00 HE
|
Passage Bio
PHILADELPHIA, May 10, 2021 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for rare, monogenic central...
Passage Bio Reports First Quarter 2021 Financial Results and Recent Business Highlights
05 mai 2021 07h00 HE
|
Passage Bio
Dosed first patient with infantile GM1 gangliosidosis in Imagine-1 Phase 1/2 trial of PBGM01, initial safety and 30-day biomarker data expected 4Q21Received multiple regulatory clearances for clinical...
Passage Bio Partners with InformedDNA® to Offer Genetic Counseling and Testing for Patients with Frontotemporal Dementia (FTD), a Form of Early Onset Dementia
03 mai 2021 07h00 HE
|
Passage Bio
No-cost genetic screening and counseling program aimed at identifying FTD patients who have certain inherited genetic mutations to guide early treatment intervention and awareness of clinical...